Articles by Tarek Sahmoud, MD
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD 21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer
ByErika P. Hamilton, MD,Sung-Bae Kim,Neelima Vidula, MD,Simona Scartoni,Tarek Sahmoud, MD,Bartomeu Piza Vallespir,Kathy Puyana Theall,Nassir Habboubi,Nuhad Ibrahim, MD 55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy 
Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer
ByGiuseppe Giaccone, MD, PhD,Pieter E. Postmus, MD, PhD,Ted A. W. Splinter, MD,Maria Diaz-puente, MD,Nico Van Zandwijk, MD, PhD,Giorgio V. Scagliotti, MD, PhD,Andrea Ardizzoni, MD,Jan Van Meerbeeck, MD,Channa Debruyne, MD,Tarek Sahmoud, MD A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative